Proteon Therapeutics Inc (PRTO): Deerfield Management Discloses Post-IPO 6.7% Stake
James E.
Posts Tagged ‘Deerfield Management’
Alimera Sciences Inc (ALIM) & Bio Blast Pharma Ltd (ORPN): 2 Pharmaceutical Stocks Hedge Funds are Increasing Their Stakes In
Pharmaceuticals and life sciences as a sector is where most of the money from hedge funds seems to be flowing in.
Entegris Inc (ENTG), Dicerna Pharmaceuticals Inc (DRNA): GMT Capital and Deerfield Management Report Their Latest Moves
In two new filings, Thomas E. Claugus' GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG).
Keryx Biopharmaceuticals (KERX): Baupost Group Boosts Its Stake
Seth Klarman is bullish on Keryx Biopharmaceuticals (NASDAQ:KERX) and his fund, Baupost Group, has recently surged its position in the company.
PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH): Broadfin Capital and Becker Drapkin Management’s Recent Bullish Moves
Last Friday, Kevin Kotler’s Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH).
Visium Asset Management and Deerfield Management Are Bullish About These Stocks
Two Schedule 13G forms filed with the SEC yesterday called my attention.
Loxo Oncology Inc (LOXO): Deerfield Management Discloses 13.65% Activist Stake
Samuel Isaly's Orbimed Advisors has disclosed holding a stake in Loxo Oncology Inc (NASDAQ:LOXO).
AMAG Pharmaceuticals Inc. (AMAG): Deerfield Management Boosts Stake to Nearly 6%
Deerfield Management, managed by James E. Flynn, has disclosed upping its stake in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). A new filing with the U.S.
Deepak Gulati’s Argentiere Capital’s Top Stock Picks
Zug, Switzerland-based Argentiere Capital is an alternative investment management firm, which was founded by Deepak Gulati. Mr.
Deerfield Management Ups Stake in Aerie Pharmaceuticals Inc (AERI)
In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI).
James E. Flynn’s Deerfield Management Reveals Passive Stake in Amphastar Pharmaceuticals Inc. (AMPH)
James E. Flynn, the manager of Deerfield Management, has disclosed a new passive stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH). Mr.
Felix Baker Raises Stake in Synageva BioPharma Corp (GEVA) Through Convention of Options
As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix Bakers' Baker Bros Advisors, a fund focused on the biotechnology and healthcare companies...
Deerfield Management Discloses New Position in ANI Pharmaceuticals Inc (ANIP)
James E. Flynn's Deerfield Management reported a new stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Deerfield Ups Stake In Trivascular Technologies Inc (TRIV)
Deerfield Management, managed by James E. Flynn, has revealed raising its position in Trivascular Technologies Inc (NASDAQ:TRIV).
Deerfield Management Reveals Position in Newly Public Company Trivascular Technologies Inc (TRIV)
As a new filing with the Securities and Exchange Commission showed, Deerfield Management, a healthcare focused investment firm, managed by James E.
Broadwood Capital Reduces Futher Questcor Pharmaceuticals Inc (QCOR)
In its filing with the Securities and Exchange Commission, Neal C.
James Flynn, Deerfield Management Boost Stake in Streamline Health Solutions Inc. (STRM)
James E. Flynn, the manager of Deerfield Management, is still bullish on Streamline Health Solutions Inc. (NASDAQ:STRM).
James Flynn, Deerfield Management Step Up Interest In Alphatec Holdings Inc (ATEC)
James E. Flynn, the manager of Deerfield Management, is bullish on Alphatec Holdings Inc (NASDAQ:ATEC).
Adage Capital Management Discloses New Stake in OvaScience Inc (OVAS)
A new filing with the SEC shows that Phill Gross and Robert Atchinson's Adage Capital Management has initiated a stake in OvaScience Inc (NASDAQ:OVAS).
Deerfield Management Boosts Its Stake in OvaScience Inc (OVAS)
Deerfield Management, led by James E.
Deerfield Management Further Raises Its Position in Auspex Pharmaceuticals Inc (ASPX)
James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported further raising its stake Auspex Pharmaceuticals Inc (NASDAQ:ASPX).
Deerfield Management Adds Cara Therapeutics Inc. (CARA) To Its Equity Portfolio
James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported a position in Cara Therapeutics Inc. (NASDAQ:CARA).
Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO)
James E. Flynn's Deerfield Management has reported adding KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) to its equity portfolio.
Hedge Fund Highlights: Warren Buffett, Bill Ackman & Richard Gerson
With four years remaining, Warren Buffett has a commanding lead in a decade-long bet that put a low-fee stock index fund up against a portfolio of high-priced hedge funds.
Deerfield Management Discloses Stake in Post-IPO Auspex Pharmaceuticals Inc (ASPX)
James E. Flynn's Deerfield Management has revealed holding shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX), a company that went public today, on February 5.
Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)
In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E.
Tang Capital Management Discloses Moves into La Jolla Pharmaceutical Company (LJPCD), Vanda Pharmaceuticals Inc. (VNDA), Mirati Therapeutics Inc. (MRTX) & Others
Tang Capital Management, led by Kevin C. Tang, revealed in a filing several moves that have impacted its equity portfolio.
Baker Bros. Advisors Reduces Exposure to MEI Pharma Inc (MEIP) to 3.4%
Julian and Felix Baker's Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares revealed as held earlier.
Deerfield Management Initiates Passive Stake in Horizon Pharma Inc (HZNP)
James E. Flynn's healthcare-focused Deerfield Management has revealed, in a new filing with the SEC, initiating a passive stake in Horizon Pharma Inc (NASDAQ:HZNP).
James E. Flynn, Deerfield Management Increase Stake in Universal American Corporation (UAM)
Deerfield Management, managed by James E.
James Flynn Reports a 4% Position in Cancer Genetics
A new filing with the Securities and Exchange Commission has revealed that James E.
James Flynn, Deerfield Buy RNA-Themed Prosensa
James Flynn, Deerfield: Prosensa Holding NV (NASDAQ:RNA) recently became an addition in the equity portfolio of Deerfield Management, managed by James E. Flynn.
Hedge Funds Are Selling BioDelivery Sciences International, Inc. (BDSI)
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Is Cross Country Healthcare, Inc. (CCRN) Going to Burn These Hedge Funds?
If you were to ask many investors, hedge funds are viewed as useless, outdated investment vehicles of a forgotten age.
Should You Buy Pacific Biosciences of California (PACB)?
To the average investor, there are tons of metrics shareholders can use to analyze Mr. Market. A duo of the best are hedge fund and insider trading interest.
Do Hedge Funds and Insiders Love Integra Lifesciences Holdings Corp (IART)?
If you were to ask many market players, hedge funds are viewed as useless, old investment vehicles of an era lost to time.
Should You Avoid Merge Healthcare Inc. (MRGE)?
To many of your peers, hedge funds are seen as useless, old investment vehicles of a period lost to current times.
Hedge Funds Are Selling eHealth, Inc. (EHTH)
If you were to ask many investors, hedge funds are perceived as overrated, old investment vehicles of a period lost to current times.
Hedge Funds Aren’t Crazy About Vocera Communications Inc (VCRA) Anymore
In today’s marketplace, there are a multitude of gauges shareholders can use to monitor their holdings.
This Metric Says You Are Smart to Buy Air Methods Corp (AIRM)
If you were to ask many of your peers, hedge funds are perceived as delayed, outdated investment vehicles of an era lost to time.
Do Hedge Funds and Insiders Love AstraZeneca plc (ADR) (AZN)?
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Edwards Lifesciences Corp (EW): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
To the average investor, there are a multitude of methods shareholders can use to monitor publicly traded companies.
Is XenoPort, Inc. (XNPT) Going to Burn These Hedge Funds?
At the moment, there are plenty of metrics market participants can use to monitor the equity markets.
Hedge Funds Are Dumping HeartWare International Inc (HTWR)
In the 21st century investor’s toolkit, there are plenty of metrics investors can use to monitor publicly traded companies.
Depomed Inc (DEPO): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
In the eyes of many market players, hedge funds are viewed as delayed, outdated financial vehicles of an era lost to time.
This Metric Says You Are Smart to Buy Sagent Pharmaceuticals Inc (SGNT)
If you were to ask many of your fellow readers, hedge funds are seen as useless, old investment tools of a forgotten age.
